Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Donna S. Neuberg, D.Sc.

Co-Author

This page shows the publications co-authored by Donna Neuberg and Jennifer Brown.
Connection Strength

2.339
  1. Obatoclax in combination with fludarabine and rituximab is well-tolerated and shows promising clinical activity in relapsed chronic lymphocytic leukemia. Leuk Lymphoma. 2015; 56(12):3336-42.
    View in: PubMed
    Score: 0.160
  2. Controversial fluorescence in situ hybridization cytogenetic abnormalities in chronic lymphocytic leukaemia: new insights from a large cohort. Br J Haematol. 2015 Sep; 170(5):694-703.
    View in: PubMed
    Score: 0.159
  3. A phase I study of escalated dose subcutaneous alemtuzumab given weekly with rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma. Haematologica. 2013 Jun; 98(6):964-70.
    View in: PubMed
    Score: 0.138
  4. Integrative genomic analysis implicates gain of PIK3CA at 3q26 and MYC at 8q24 in chronic lymphocytic leukemia. Clin Cancer Res. 2012 Jul 15; 18(14):3791-802.
    View in: PubMed
    Score: 0.129
  5. Phase II study of dasatinib in relapsed or refractory chronic lymphocytic leukemia. Clin Cancer Res. 2011 May 01; 17(9):2977-86.
    View in: PubMed
    Score: 0.119
  6. Comparison of familial and sporadic chronic lymphocytic leukaemia using high resolution array comparative genomic hybridization. Br J Haematol. 2010 Nov; 151(4):336-45.
    View in: PubMed
    Score: 0.115
  7. A phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomas. Br J Haematol. 2009 Jun; 145(6):741-8.
    View in: PubMed
    Score: 0.104
  8. Prevalence of familial malignancy in a prospectively screened cohort of patients with lymphoproliferative disorders. Br J Haematol. 2008 Nov; 143(3):361-8.
    View in: PubMed
    Score: 0.100
  9. Long-term survival after autologous bone marrow transplantation for follicular lymphoma in first remission. Biol Blood Marrow Transplant. 2007 Sep; 13(9):1057-65.
    View in: PubMed
    Score: 0.092
  10. Increasing incidence of late second malignancies after conditioning with cyclophosphamide and total-body irradiation and autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol. 2005 Apr 01; 23(10):2208-14.
    View in: PubMed
    Score: 0.078
  11. Autologous bone marrow transplantation for marginal zone non-Hodgkin's lymphoma. Leuk Lymphoma. 2004 Feb; 45(2):315-20.
    View in: PubMed
    Score: 0.073
  12. Activation of Notch and Myc signaling via B cell-restricted depletion of Dnmt3a generates a consistent murine model of chronic lymphocytic leukemia. Cancer Res. 2021 Oct 22.
    View in: PubMed
    Score: 0.062
  13. Longitudinal single-cell dynamics of chromatin accessibility and mitochondrial mutations in chronic lymphocytic leukemia mirror disease history. Cancer Discov. 2021 Jun 10.
    View in: PubMed
    Score: 0.061
  14. Preneoplastic Alterations Define CLL DNA Methylome and Persist through Disease Progression and Therapy. Blood Cancer Discov. 2021 Jan; 2(1):54-69.
    View in: PubMed
    Score: 0.058
  15. Distinct evolutionary paths in chronic lymphocytic leukemia during resistance to the graft-versus-leukemia effect. Sci Transl Med. 2020 09 16; 12(561).
    View in: PubMed
    Score: 0.058
  16. Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies. Cancer Cell. 2019 10 14; 36(4):369-384.e13.
    View in: PubMed
    Score: 0.054
  17. Growth dynamics in naturally progressing chronic lymphocytic leukaemia. Nature. 2019 06; 570(7762):474-479.
    View in: PubMed
    Score: 0.053
  18. Phase 1 study of lenalidomide, bendamustine, and rituximab in previously untreated patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2019 12; 60(12):2931-2938.
    View in: PubMed
    Score: 0.052
  19. Integrated single-cell genetic and transcriptional analysis suggests novel drivers of chronic lymphocytic leukemia. Genome Res. 2017 08; 27(8):1300-1311.
    View in: PubMed
    Score: 0.046
  20. High-level ROR1 associates with accelerated disease progression in chronic lymphocytic leukemia. Blood. 2016 12 22; 128(25):2931-2940.
    View in: PubMed
    Score: 0.044
  21. Transcriptomic Characterization of SF3B1 Mutation Reveals Its Pleiotropic Effects in Chronic Lymphocytic Leukemia. Cancer Cell. 2016 Nov 14; 30(5):750-763.
    View in: PubMed
    Score: 0.044
  22. Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition. Nat Commun. 2016 05 20; 7:11589.
    View in: PubMed
    Score: 0.043
  23. Locally disordered methylation forms the basis of intratumor methylome variation in chronic lymphocytic leukemia. Cancer Cell. 2014 Dec 08; 26(6):813-825.
    View in: PubMed
    Score: 0.039
  24. Imatinib mesylate lacks efficacy in relapsed/refractory peripheral T cell lymphoma. Leuk Lymphoma. 2015 Apr; 56(4):993-8.
    View in: PubMed
    Score: 0.038
  25. Lenalidomide and rituximab for the initial treatment of patients with chronic lymphocytic leukemia: a multicenter clinical-translational study from the chronic lymphocytic leukemia research consortium. J Clin Oncol. 2014 Jul 01; 32(19):2067-73.
    View in: PubMed
    Score: 0.037
  26. Somatic mutation as a mechanism of Wnt/ß-catenin pathway activation in CLL. Blood. 2014 Aug 14; 124(7):1089-98.
    View in: PubMed
    Score: 0.037
  27. Autologous CLL cell vaccination early after transplant induces leukemia-specific T cells. J Clin Invest. 2013 Sep; 123(9):3756-65.
    View in: PubMed
    Score: 0.035
  28. Detection of circulating tumour DNA in patients with aggressive B-cell non-Hodgkin lymphoma. Br J Haematol. 2013 Oct; 163(1):123-6.
    View in: PubMed
    Score: 0.035
  29. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell. 2013 Feb 14; 152(4):714-26.
    View in: PubMed
    Score: 0.034
  30. Oral clofarabine for relapsed/refractory non-Hodgkin lymphomas: results of a phase 1 study. Leuk Lymphoma. 2013 Sep; 54(9):1915-20.
    View in: PubMed
    Score: 0.034
  31. Nanowire-mediated delivery enables functional interrogation of primary immune cells: application to the analysis of chronic lymphocytic leukemia. Nano Lett. 2012 Dec 12; 12(12):6498-504.
    View in: PubMed
    Score: 0.034
  32. Risk factors for development of pneumonitis after high-dose chemotherapy with cyclophosphamide, BCNU and etoposide followed by autologous stem cell transplant. Leuk Lymphoma. 2012 Jun; 53(6):1130-6.
    View in: PubMed
    Score: 0.031
  33. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med. 2011 Dec 29; 365(26):2497-506.
    View in: PubMed
    Score: 0.031
  34. MicroRNA expression profiling identifies activated B cell status in chronic lymphocytic leukemia cells. PLoS One. 2011 Mar 08; 6(3):e16956.
    View in: PubMed
    Score: 0.030
  35. Standardization of fluorescence in situ hybridization studies on chronic lymphocytic leukemia (CLL) blood and marrow cells by the CLL Research Consortium. Cancer Genet Cytogenet. 2010 Dec; 203(2):141-8.
    View in: PubMed
    Score: 0.029
  36. Self-administered, subcutaneous alemtuzumab to treat residual disease in patients with chronic lymphocytic leukemia. Cancer. 2011 Jan 01; 117(1):116-24.
    View in: PubMed
    Score: 0.029
  37. Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. Blood. 2008 Sep 01; 112(5):1923-30.
    View in: PubMed
    Score: 0.025
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.